Epix Delaware, Inc.

Nanotherapeutics, Inc.

Cytopathfinder, Inc.

Pradyumna Mohanty

Yael Marantz

Dongli Chen

Sharon Shacham

Oren Becker

Silvia Noiman

Dale S Dhanoa

Boaz Inbal

Alexander Heifetz

Shay Bar-Haim

Mercedes Lobera

Laurence Wu

Merav Fichman

Srinivasa Rao Cheruku

Anurag Sharadendu

Raphael Nudelman

Shomir Ghosh

Jian Lin

Zhaoda Zhang

Steffi Koerner

Efrat Ben-Zeev

Sharon Shachem

Rosa E Melendez

Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein. 

Carboxamide compounds and their use

The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Thienopyridinone compounds and methods of treatment

The invention generally relates to thienopyridinone 5-HTreceptor modulators, and in particular the use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating Alzheimer's disease, cognition disorders, depression, and anxiety.

Compositions and methods for treating CNS disorders

Synthesis of thienopyridinone compounds and related intermediates

The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Arylpiperazinyl compounds

The invention relates to 5-HT receptor agonists and partial agonists. Thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

The invention relates to 5-HTreceptor agonists and partial agonists. Thienopyridinone compounds and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HTreceptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, Parkinson's disease, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, and nonulcer dyspepsia. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formulae I: and II, and synthesis and uses of those compounds for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Growing community of inventors

Woburn, MA, United States of America

Pradyumna Mohanty